The Antibody and BioResource (ABR) Core is a vibrant facility that contributes broadly to the basic and translational mission of the Center by focusing on two tools central to reproducibile research, specifically antibodies and cell lines. The Core works with researchers to develop new monoclonal antibodies (MAbs) against their target(s) of interest that will work in the required application(s). When antibodies are not readily available elsewhere, particularly newly developed at MSK, the facility provides access to essential MAbs by: 1) Producing (in vitro); 2) Purifying; 3) Conjugating (to fluorphores and proteins); and/or 4) Fragmenting them into Fab or F(Ab?)2 fragments. To promote the use of healthy cell cultures, which is central to generating reproducable data from these in vitro systems, the ABR Core offers a mycoplasma testing service. Well authenticated cell lines created at MSK and deposited into the Core are distributed to researchers around the world, which ensures the tools that the Cancer Center is sharing are of the highest quality. Relevant information and testing results on curated cell lines are also shared with recipients. These include, but are not limited to, a description and history of the line, references, culture conditions, unique characteristics, STR profiles for authentication purposes of human cell lines, images of the cells, confirmation that no mycoplasma was detectable in the culture, karyotyping, and appropriate flow cytometric analysis. During the past grant period the ABR Core has contributed to 50 publications for researchers from seven of the 10 CCSG Programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084816
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Deng, Pujuan; Zhou, Yuqiao; Jiang, Junyi et al. (2018) Transcriptional elongation factor Paf1 core complex adopts a spirally wrapped solenoidal topology. Proc Natl Acad Sci U S A 115:9998-10003
Bellelli, Roberto; Vitagliano, Donata; Federico, Giorgia et al. (2018) Oncogene-induced senescence and its evasion in a mouse model of thyroid neoplasia. Mol Cell Endocrinol 460:24-35
Signoretti, Sabina; Flaifel, Abdallah; Chen, Ying-Bei et al. (2018) Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. J Clin Oncol :JCO2018792259
D'Agostino, Thomas A; Shuk, Elyse; Maloney, Erin K et al. (2018) Treatment decision making in early-stage papillary thyroid cancer. Psychooncology 27:61-68
Turcot, Valérie (see original citation for additional authors) (2018) Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nat Genet 50:26-41
Moryl, Natalie; Dave, Vinnidhy; Glare, Paul et al. (2018) Patient-Reported Outcomes and Opioid Use by Outpatient Cancer Patients. J Pain 19:278-290
Vickers, Andrew J; Vertosick, Emily A; Lewith, George et al. (2018) Acupuncture for Chronic Pain: Update of an Individual Patient Data Meta-Analysis. J Pain 19:455-474
Muhsen, Shirin; Moo, Tracy-Ann; Patil, Sujata et al. (2018) Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy. Ann Surg Oncol 25:1912-1920
Gupta, Piyush; Migliacci, Jocelyn C; Montero, Pablo H et al. (2018) Do we need a different staging system for tongue and gingivobuccal complex squamous cell cancers? Oral Oncol 78:64-71
Giri, Veda N; Knudsen, Karen E; Kelly, William K et al. (2018) Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol 36:414-424

Showing the most recent 10 out of 8799 publications